CD20×CD3 bispecific T‑cell–engaging antibody that redirects T cells via CD3 to kill CD20+ B cells (IV).
Humanized bispecific antibody that binds CD20 on B cells and CD3 on T cells, crosslinking them to redirect and activate T cells to kill CD20+ B cells.
Bispecific antibody binds CD20 on B cells and CD3 on T cells, crosslinking them to activate T cells and induce perforin/granzyme-mediated killing of CD20+ cells.
Anti‑CD79b antibody–drug conjugate that delivers the microtubule‑disrupting cytotoxin MMAE to B cells (IV).
Anti-CD79b monoclonal antibody–drug conjugate linked via a protease-cleavable linker to monomethyl auristatin E (MMAE). After binding CD79b on B cells and internalization, the linker is cleaved to release MMAE, which inhibits tubulin polymerization, causing G2/M arrest and apoptosis of malignant B cells.
The anti-CD79b ADC binds CD79b, is internalized, and releases MMAE, which inhibits tubulin polymerization, causing G2/M arrest and apoptosis of the target-expressing cells.
Fc‑engineered anti‑CD19 monoclonal antibody that enhances ADCC/ADCP against CD19+ B cells (IV).
Humanized, Fc‑engineered anti‑CD19 monoclonal antibody that binds CD19 on malignant and normal B cells and engages Fcγ receptors on effector cells to enhance antibody‑dependent cellular cytotoxicity (ADCC) and antibody‑dependent cellular phagocytosis (ADCP), leading to depletion of CD19+ B cells.
Binds CD19 on B cells and engages Fcγ receptors on effector cells to trigger ADCC and ADCP, leading to depletion/killing of CD19+ cells.
Autologous T cells engineered to express a chimeric antigen receptor targeting BCMA (TNFRSF17) on malignant plasma cells, mediating cytotoxicity via perforin/granzyme and cytokine release.
Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting BCMA (TNFRSF17) on malignant plasma cells. Antigen engagement activates the T cells to proliferate and kill BCMA-expressing cells via perforin/granzyme-mediated cytotoxicity and cytokine release.
BCMA-directed CAR T cells bind BCMA on target cells, become activated, and kill them via T cell cytotoxicity—primarily perforin/granzyme-mediated lysis (with possible Fas/FasL and cytokine-mediated apoptosis).
Investigational intravenous antibody-drug conjugate (ADC) that binds a tumor-associated surface antigen and delivers an intracellular cytotoxic payload to kill antigen-expressing cancer cells.
Human anti–folate receptor alpha (FRa) antibody-drug conjugate that binds FRa on tumor cells, is internalized, and releases a camptothecin-based topoisomerase I inhibitor (AZ14170132). The payload inhibits TOP1, causing DNA replication stress and single- and double-strand breaks, leading to cell-cycle arrest and apoptosis in FRa-expressing cancer cells.
An FRa-targeted antibody-drug conjugate binds FRa on tumor cells, is internalized, and releases a camptothecin-based topoisomerase I inhibitor that induces DNA damage, causing cell-cycle arrest and apoptosis of FRa-expressing cells.